Search Results - antibody-dependent+cellular+cytotoxicity

2 Results Sort By:
High Efficacy Vaccine and Microbicide Combination For Use Against HIV
Abstract: Human immunodeficiency virus (HIV) remains a major global health challenge despite the advancement made in development of effective antiretrovirals (ARVs). ARVs are effective at limiting replication and spread of the virus, and progression to acquired immuno-deficiency syndrome (AIDS). However, ARVs often lead to emergence of drug-resistant...
Published: 8/5/2024   |   Inventor(s): Genoveffa Franchini, Marjorie Robert-Guroff, Daniel Appella, Sabrina Helmold Hait, Mohammed Rahman, Massimiliano Bissa, Ettore Appella, Lisa Marie Jenkins, Isabela Silva De Castro
Keywords(s): Acquired Immuno-Deficiency Syndrome, ADCC, AIDS, Antibody-dependent Cellular Cytotoxicity, Efferocytosis, Envelope Glycoprotein 120, Envelope Variable Region, Franchini, gp120, HIV, Human Immunodeficiency Virus, Microbicide, SAMT-247, V1, Vaccine
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Application > Vaccines
Fully Human Antibody Targeting Tumor Necrosis Factor Receptor Type 2 (TNFR2) for Cancer Immunotherapy
Abstract: Tumor necrosis factor receptor type 2 (TNFR2)-expressing regulatory T cells (Tregs), present in the tumor microenvironment, play an important role in tumor immune evasion. TNFR2 plays a crucial role in stimulating the activation and proliferation of Tregs, a major checkpoint of antitumor immune responses. In addition to its expression on Tregs,...
Published: 5/22/2024   |   Inventor(s): Joost Oppenheim, Dimiter Dimitrov, De Yang, Xin Chen, Zhongyu Zhu
Keywords(s): ADCC, ANTIBODY, Antibody-dependent Cellular Cytotoxicity, CANCER, Immunotherapy, Oppenheim, TNFR2, Tregs, Tumor Necrosis Factor Receptor Type 2
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology